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Abstract
Increasing the secretion of reactive oxygen intermediates (ROI) by monocytes in the synovial fluid is an 
indicator to determine the severity of joint inflammation. Previous studies have shown that curcumin inhibit 
the osteoarthritis progression with its ability to inhibite the activity of the nitric oxide synthase (NOS) enzyme 
from macrophages. In this prospective randomized open end blinded evaluations = PROBE study, 80 patients 
with knee osteoarthritis were eligable. The subject were devided in to two group: group who received 3 x 30 
mg of curcuminoid from Curcuma domestica Val. extract (curcuminoid group) and group who received 3 x 25 
mg of diclofenac sodium (diclofenac group) as comparison. The treatment was for 4 weeks time. The secretion 
of ROI by sinovial fluid monocytes was calculated by scoring the amount of formazan formation after neutral 
red staining in nitrobleu tetrazolium reduction assay. The result of this study showed that the secretion of ROI 
by synovial fluid monocytes was significantly decreased in both groups (p <0.001) respectively. There was 
no significant difference in decreasing of ROI secretion of synovial fluid monocytes between both treatment 
groups (p = 0.92).
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Introduction
Osteoarthritis (OA) is the most often 
joint disease found in people. The disease is 
a major cause of musculoskeletal disorders 
throughout the world and become the sec 
largest cause of physical disability after 
ischemic heart disease for over 50 years of 
age. This disease causes loss of working h and 
high cost of treatment (Dieppe, 2008).  The 
prevalence of OA increases with increasing 
of age (Breedveld, 2004).
Pathophysiology of OA is mixed 
between the process of degeneration 
and inflammation, it is evidenced by 
the degeneration of cartilage which is 
accompanied by an increase in leukocyte 
count and pro-inflammatory cytokines in 
synovial fluid of affected joints (Ratiner et 
al., 2001). In OA there is imbalance between 
synthesis and degradation of joint cartilage, 
and subchondral bone. Joint degradation 
is initiated by mechanical loading which 
resulting in chondrocyte metabolism 
disorders, production of proteolytic enzymes 
such as matrix metalloproteinase (MMP) and 
damage of joint cartilage. The occurrence of 
multiple microfractur cause degradation and 
depletion of vulnerable joints, changes in joint 
architecture and the formation of osteophyte. 
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If it happen, the osteoarthritis progression 
will continue. Changes in architecture of the 
joint resulting in joint mechanics change that 
cause increase pressure on the joints, further 
joint damage, release of damage enzymes 
and inflammation of the joints (Berenbaum, 
2008). In the elimination process of foreign 
antigens or when interacting with stimuli 
such as cytokines, the oxidative burst 
of monocytes showed an increased capacity 
to produce ROI in large quantities. Reactive 
oxygen intermediates play an important  role 
in the process of inflammation and tissue 
damage (Felson, 2008)
The study of anti-inflammatory activity 
of curcumin has been done. Curcumin 
one component of curcuminoid has more 
powerful anti-inflammatory activity than 
the other components (Parslow & Bainton, 
2003). In vitro curcumin inhibite the 
activity of phospholypase, lypoxigenase, 
cycloxigenase-2 (COX-2), leucotrien, 
prostaglandin, thromboxane, Nitric Oxide, 
collagenase, elastase, hyaluronidase, 
interferon, TNF-α and IL-12. In people with 
rheumatoid arthritis, curcumin reduces 
the stiffness, swollen joints and walking 
time. Curcumin also suppressed the post-
operative inflammation (Joe et al., 2004). 
Secretion of ROI by monocytes in the 
synovial fluid determine the severity of 
joint inflammation. Two important mediators 
produced by monocytes in the synovial fluid 
in initiate the inflammatory process and 
elimination of antigen are COX-2 enzyme 
and reactive oxygen intermediates (ROI). 
Increasing of ROI secretion by monocytes 
in the synovial  f luid will  follow by 
increasing of joint inflammation (Chainani, 
2003). Production of nitric oxide and oxygen 
radicals in chondrocytes are affected by 
the biological process of osteoarthritis and 
rheumatoid arthritis (Mazzetti et al., 2001). The 
results of previous studies have shown that 
curcumin inhibits the osteoarthritis process 
(Ukil et al., 2003).
This study aim to assess the ability of 
curcuminoid from Curcuma domestica Val. 
rhyzome extract in inhibit the ROI secretion of 
synovial fluid monocytes in osteoarthritis. 
Materials and Methods
Research design
This is a prospective randomized open 
end blinded evaluation (PROBE) study.
Materials
Extraction was done by sorted the 
Curcuma domestica Val. rhyzome then 
washed, cut into pieces with a thickness of 1-2 
mm and dried with drying cupboard for 24 
h at 40 0 C to obtain maximum water content 
of 10% v/w. After dry it was made to be 
some powder. The powder was mixed with 
ethanol and then macerated (soaked) for 24 
h, then filtered with a Buchner funnel (with 
vacuum pressure). Collected filtrate was 
evaporated at 45 0 C in vacuum condition. For 
the determination of curcuminoids curcumin 
standard solution used with varying degrees 
of concentration. Extract obtained was diluted 
to 100 mg/mL and touched on silica gel GF 
254 plates and then eluted with a mobile 
phase system chloroform-methanol (97-3) 
v/w. Detection of spots is done by ultraviolet 
light 254 nm and 365 nm. The scan was then 
performed by Thin Layer Chromatography 
scanner. The level of curcumin, desmetoxi 
curcumin and bisdesmetoxi curcumin as 
components of curcuminoids was calculated 
by linear regression method. The extract was 
entered in the capsuls which the dose of 30 
mg curcuminoid. The other capsules contain 
25 mg of sodium diclofenac.
Research subjects
This study was run at the Rheumatology 
Clinic, Department of Internal Medicine 
Faculty of Medicine, Universitas Gadjah 
Mada/Dr. Sardjito Hospital - Yogyakarta. The 
study population were patients with knee OA, 
registered and were still controlled in Dr. Sardjito 
General Hospital. Random selection was done 
among 168 patients to find 80 patients who 
eligible in this research. The subjects have 
no arthritis other than osteoarthritis, had 
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no abnormalities of liver, kidney or bone 
marrow function, did not have any history of 
gastritis, peptic or duodenal ulcer, no history 
of hypersensitivity to diclofenac sodium and 
curcuminoid, did not use anti-coagulant 
medication or other anti-inflammatory drugs, 
and agree to follow the study with signed the 
informed consent. 
After 1 week washed-out, the random 
assignment was done so that the sample was 
divided into treatment groups and control 
groups. The treatment was for 4 weeks period. 
The treatment group were given 3 x 30 mg 
curcuminoid from Curcuma Val. rhyzome 
extract, while the control group were given 
3 x 25 mg diclofenac sodium. Assessment of 
the treatment results was performed before 
and after 4 weeks treatment by scoring the 
formazan sedimentation in the cytoplasm of 
monocytes. Data analysis was conducted on 
the amount of ROI secretion by synovial fluid 
monocytes before and after treatment. 
Laboratory examination
Before starting the treatment, 2 mL of 
synovial fluid was taken from the affected knee. 
The culture of monocytes by PMA stimulation 
was performed. By nitroblue tetrazolium (NBT) 
reduction assay, the formazan sedimentation 
was able to assess. Since the formazan is the 
end result of the reaction between the NBT and 
ROI, the amount of ROI secretion by synovial 
fluid monocytes were calculated by scoring 
the formazan sedimentation in the cytoplasm 
of monocytes. Monocytes culture was added 
by 500 ul NBT solution containing 125 ng/mL 
PMA and incubated at 37 o C and 5% CO2 for 
60 min. Cells was then washed 3 times with 
PBS, dried at room temperature and fixed 
in absolute methanol for 30 sec and painted 
with neutral red solution for 15 min and then 
washed with distilled water then dried at room 
temperature and ready to be observed. The 
cytoplasm of monocytes without secreted ROI 
was pale, while that secreted ROI looks blue 
insoluble formazan sedimentation as a result 
of ROI and NBT reaction. Based on the amount 
of formazan sedimentation the monocytes were 
differentiated into 4 groups. Without secreted 
ROI (no formazan deposits in the cytoplasm, 
given the value 0), which secreted a little amount 
of ROI (maximum formazan sedimentation 
reaches a quarter of the cytoplasm, given the 
value 1), which secreted ROI in large quantities 
(formazan sedimentation between a quarter 
to three-quarter of the cytoplasm, given the 
value 2) and which secreted ROI in a very large 
quantities (more than three-quarter formazan 
sedimentation of the cytoplasm, given the 
value 3) (Figure 1). 
Figure 1. Secretion of ROI by synovial fluid 
monocytes
Before the study started, firstly the 
researchers test the value of kappa to determine 
intraobserver and interobserver consistency 
of the ROI value secreted by monocytes in 
the synovial fluid. Observation was done 
by two assessor. Each assessor observed 
40 monocytes then calculated the value of 
intraobserver and interobserver consistency. 
In assessing the effectiveness of the treatments 
each assessor observed 100 monocytes in 
each preparate before starting the treatmen 
and after 4 weeks treatment.
Statistical analysis
Unpaired  Student's  -  t  test  was 
performed for analysis. 
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Results and Discussions 
A total of 80 patients with knee 
osteoarthritis were eligible and willing to 
participate in this study. Subjects were divided 
randomly into two groups: the treatment group 
(named curcuminoid group) were given 3 x 
30 mg curcuminoid from Curcuma domestica 
Val. rhyzome  extract,  while the control group 
(named diclofenac group) were given 3 x 25 mg 
diclofenac sodium. 
In curcuminoid group number of subjects 
who participated in the study were 39 patients 
consisting of 15 men and 24 women. The mean 
age was 64.05 ± 8.83 years.  The duration 
suffering of osteoarthritis was 41.23 ± 32.60 
months. The body mass index was 26.28 ± 
3.62 kg / m 2. Five subjects were excluded 
from the study with the reasons: 1 Subject 
drank piroxicam, 1 subject experienced ureter 
colic due to urinary tract stones, 1 subject had 
hematuria due to tumor of vesica urinaria, 1 
subject stopped the curcuminoid treatment as 
his family request and 1 subject experienced 
an acute exacerbation of chronic obstructive 
pulmonary disease. Number of subjects in the 
curcuminoid group who finished the study 
was 34 patients, comprising 11 men and 23 
women.
In diclofenac group the number of 
subjects who participated in the study were 
41 patients consisting of 12 men and 29 
women. The mean age was 64.56 ± 8.86 years. 
The duration suffering of osteoarthritis was 
40.37 ± 30.87 months. The body mass index 
was 26.44 ± 4.79 kg / m 2. Two subjects were 
excluded from the study with the reasons: 1 
subject experiencing dyspepsia on the seventh 
day of treatment which did not improve by 
giving omeprazole 10 mg 1 tablet daily and 
1 subject has no synovial fluid in aspiration. 
Number of subjects in the diclofenac group 
who finished the study was 39 patients, 
comprising 11 men and 28 women. 
ROI secretion by monocytes before 
treatment were 2.25 ± 0.23 in the curcuminoid 
group while 2.20 ± 0.21 in diclofenac 
group. Reactive oxygen intermediates play 
an important role in the process of 
inflammation and tissue damage. Exposure 
of ROI to normal cells will cause a variety 
of pathological changes leading to cell and 
tissue damage for example in pathogenesis 
of osteoarthritis (Ahmed et al., 2005; Shah 
et al., 2005). Monocytes from patients with 
rheumatoid arthritis release increase amount 
of reactive oxygen intermediates. Reactive 
oxygen intermediates play an important role 
in the process of cartilage degradation in the 
pathogenesis of some rheumatic diseases 
through lipid peroxidation in chondrocytes 
(Arora et al., 2000). In this study the ROI 
secretion by synovial fluid monocytes was 
not significantly different between the two 
groups (p = 0.16).
Table 1. ROI Secretion by Monocytes Before Treatment           
Variable
Mean±SD
P value
CI 95%
Curcuminoids
(n=39)
Diclofenac 
(n=41) Lower Upper
ROI secretion 2,25 ± 0,23 2,20 ± 0,21 0,16* -0,047 0,147
Description: *Independent t-test
 
Figure 2.  Distribution of ROI secretion by 
Monocytes, p = 0.200
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The distribution of ROI secretion by 
monocytes before treatment spread follow 
a normal curve with p = 0.200 (Figure 2). To 
analyze the differences of ROI secretion 
between both group the independent t – test 
was used, because subjects in curcuminoid 
group were not same to the subjects in 
diclofenac group. 
ROI secretion by synovial fluid monocytes 
was significantly decreased in both groups with 
p <0.001 respectively  (Table 2). Oxidative 
stress stimulate the   peroxidation of lipid 
membranes and able to cause a serious cells 
damage. Changes in biological condition 
of the cell membranes will increase tissue 
permeability and disrupt the normal function 
of these cells. Reactive oxygen intermediates is 
one of the oxidative markers could be detected 
in the laboratory (Tiku et al., 2000) 
In elimination process of the foreign 
antigens or when interacting with stimuli 
such as cytokines, the oxidative burst 
of monocytes showed an increased capacity to 
produce ROI in large quantities (Donne et al., 
2006). Reactive oxygen intermediates play a 
role in the process of inflammation and tissue 
damage in osteoarthritis (Shah et al., 2005). In 
experimental animals curcumin suppress 
the production of Nitrite Oxyde (NO) and 
superoxide anions (O 2 -). There are differential 
roles of  nitric oxide and oxygen radicals in 
chondrocytes affected by osteoarthritis and 
rheumatoid arthritis (Mazzetti et al., 2001). 
Curcumin inhibits the in vitro secretion of ROI 
by gum fibroblasts and human submandibular 
gland carcinoma cells (Atsumi et al., 2005). 
Curcumin Inhibits ROS Formation and 
Apoptosis in Methylglyoxal-Treated Human 
Hepatoma G2 Cells (Chan et al., 2005). The 
results of this study indicate that there was 
no significant difference in decreasing of ROI 
secretion by synovial fluid monocytes during 
treatment between the two groups (Table 
3). The ability of both drugs did not differ 
Table 2. ROI Secretion by Monocytes Before and After Treatment
Variabel
Curcuminoid
(Mean±SD) P value
CI 95% Diclofenac (Mean±SD) P value
CI 95%
Before After Lower Upper Before After Lower Upper
ROI 
secretion 2.23±0.22 0.76±0.30 <0.001* 1.37 1.57 2.21± 0.20 0.75±0.32 <0.001 1.32 1.59
Description: *Independent t-test 
Table 3. Change of ROI secretion in both groups
Variable
Mean±SD
P value
CI 95%
Curcuminoid 
(n=34)
Diclofenac 
(n=39) Lower Upper
Change of ROI secretion 1.48±0.44 1.46±0.42 0.92# -0.19 0.21
Description: #Mann Whitney U test
Table 4. Value of number needed to be treated in both groups
Therapeutic Effect
Control Event 
Rate/CER 
(Diclofenac)
Experimental 
Event Rate/EER 
(Curcuminoid)
RRR ARR NNT
Decreased secretion of 
ROI 
(Target  scores <1)
82.1% 70.6% 14.0% 11.5% 9
RRR = Relative risk reduction = |CER-EER|/CER
ARR = Absolute risk reduction = |CER-EER|
NNT = Number needed to be treated  = 1/ARR
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significantly in reducing the secretion of ROI 
by monocytes synovial fluid of patients with 
knee osteoarthritis. It is remains to be further 
investigated how the mechanism of action 
of diclofenac sodium and curcuminoid from 
Curcuma domestica Val. rhyzome  extract in 
suppressing the secretion of ROI by synovial 
fluid monocytes. 
The number needed to be treated analysis 
of the secretion of ROI by synovial fluid 
monocytes get that to obtain one subject with 
decreasing of ROI secretion with the target 
score of less than 1 in the group that received 
diclofenac sodium compared to curcuminoid 
from Curcuma domestica Val. rhyzome 
extract, the number of subjects needed to be 
treated are 9 patients (Table 4). 
Oraly treatment by curcuminoid from 
Curcuma domestica Val. rhyzome extract 
significantly inhibite the secretion of ROI by 
monocytes synovial fluid of osteoarthritic 
joint. The ability of curcuminoid from 
Curcuma domestica Val. rhyzome extract in 
inhibite the secretion of ROI by monocytes 
synovial fluid is not significantly different 
compared to diclofenac sodium.  
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